Publications
Xu MJ, Okerosi S, Nkya A, Van Loon K. Strategically striving to be more inclusive: A recommendation for gender-neutral human-papillomavirus vaccine policies. Human vaccines & immunotherapeutics. 2025. PMID: 40098479
Sorror ML, Saber W, Logan BR, Geller NL, Bellach A, Kou J, Wood WA, McCarty J, Knight TG, Runaas L, Johnston LJ, Walston JD, Nakamura R, Jarrett L, Mishra A, Uberti J, Dahi PB, Saultz JN, McCurdy SR, Morris LE, Imus P, Hogan WJ, Nadiminti KVG, Bhatt VR, Olin RL, Maakaron J, Sobecks RM, Wall SA, Mattila D, Protz B, Devine SM, Horowitz MM, Artz AS. Novel Composite Health Assessment Risk Model for Older Allogeneic Transplant Recipients: BMT-CTN 1704. Blood advances. 2025. PMID: 40101246
Moussavi-Baygi R, Ryan MJ, Sim W, Hoelscher SB, Luga V, Chandrakumar AA, Hoes L, Cha J, Lee YS, Herm K, Doron B, Ding CKC, Stohr BA, Jin P, Nadkarni T, Fang X, Haryono M, Nguyen A, Karthaus WR, Sawyers C, Feng FY, Goodarzi H, Bose R. Stochastically Emergent Tumors offer in vivo whole genome interrogation of cancer evolution from non-malignant precursors. bioRxiv : the preprint server for biology. 2025. PMID: 40166351
Janni W, Friedl TWP, Yab TC, Bidard FC, Cristofanilli M, Hayes DF, Ignatiadis M, Regan MM, Alix-Panabieres C, Barlow WE, Caldas C, Carey LA, Dirix L, Fehm T, Garcia-Saenz JA, Gazzaniga P, Generali D, Gerratana L, Gisbert-Criado R, Jacot W, Jiang Z, Joosse SA, Lianidou E, López López R, Magbanua MJM, Manso L, Mavroudis D, Müller V, Munzone E, Pantel K, Pierga JY, Rack B, Riethdorf S, Rugo HS, Sideras K, Sleijfer S, Smerage J, Stebbing J, Terstappen LWMM, Vidal-Martínez J, Wallwiener M, Giridhar KV, Liu MC. Clinical validity of repeated circulating tumor cell enumeration as an early treatment monitoring tool for metastatic breast cancer in the PREDICT global pooled analysis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 40100138
Harbeck N, Dieras V, Gelmon KA, Finn RS, Martin M, Neven P, Kim S, Ma J, Gauthier E, Broughton E, Doan J, Rugo HS. Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial. ESMO open. 2025. PMID: 40107156
Rugo HS, Bardia A, Schmid P, Tolaney SM, Dasgupta A, Kaushik A, Verret W, Gosset M, Brufsky A, Cortés J, Marmé F. Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast Cancer. Current oncology (Toronto, Ont.). 2025. PMID: 40136373
Gluz O, Xu B, Nanda R, Dasgupta A, Kaushik A, Verret W, Sharma A, Singh B, Rugo HS. Efficacy of sacituzumab govitecan versus treatment of physician's choice in previously treated HR+ and HER2- mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials. Therapeutic advances in medical oncology. 2025. PMID: 40093981
Caston NE, Deng L, Williams CP, Levitan EB, Azuero A, Griffin R, Smith KL, Wolff AC, Melisko ME, Shinn EH, Gallagher K, Angove R, Wheeler SB, Rocque GB. System-Level Transformations to Increase Patient Participation in Clinical Trials. JCO oncology practice. 2025. PMID: 40080789
Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, Morillo D, Martinez-Chamorro C, Mateos MV, Costa LJ, Caers J, Rasche L, Krishnan A, Ye JC, Karlin L, Lipe B, Vishwamitra D, Skerget S, Verona R, Ma X, Qin X, Ludlage H, Campagna M, Masterson T, Hilder B, Tolbert J, Renaud T, Goldberg JD, Kane C, Heuck C, San-Miguel J, Moreau P. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. The Lancet. Haematology. 2025. PMID: 40090350
Chari A, Bal S, Ailawadhi S, Krishnan A, Patel KK, Berdeja JG, Garfall A, Callander N, Banerjee R, Alsina M, Nooka AK, Dhakal B, Gasparetto C, Costello C. Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma. Clinical lymphoma, myeloma & leukemia. 2025. PMID: 40175263
Meric-Bernstam F, Bardia A, Bossi P, Bianchini G, Gatlin F, Lalla RV, Melosky B, Niikura N, Yap TA, Kim SS, Rajagopalan R, Fairhurst RM, Graff SL, Rugo HS. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. The oncologist. 2025. PMID: 40139260
Atkinson TM, Mazumdar M, Van Hyfte G, Lee JY, Li Y, Lynch KA, Webb A, Holland SM, Lubetkin EI, Goldstone S, Einstein MH, Stier EA, Wiley DJ, Mitsuyasu R, Rosa-Cunha I, Aboulafia DM, Dhanireddy S, Schouten JT, Levine R, Gardner EM, Dunlevy H, Barroso LF, Bucher G, Korman J, Stearn B, Wilkin TJ, Ellsworth G, Pugliese JC, Cella D, Berry-Lawhorn JM, Palefsky JM. Health-Related Quality of Life for Persons Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (AMC-A01). JCO oncology practice. 2025. PMID: 40048673
Lizeth Estrada, Farhana Moon, Le Bryan Khuong, Li Zhang, Alan Paciorek, Paige Steiding, Claire Mulvey, Emily Bergsland. Characterization of early-onset gastroenteropancreatic neuroendocrine neoplasms at UCSF. Endocrine Abstracts. 2025. PMID:
Alan Paciorek, Lizeth Estrada, Farhana Moon, Le Bryan Khuong, Li Zhang, Paige Steiding, Claire Mulvey, Emily Bergsland. Disparities in the rising incidence of early-onset neuroendocrine neoplasms. Endocrine Abstracts. 2025. PMID:
Bejan CA, Wang M, Venkateswaran S, Bergmann EA, Hiles L, Xu Y, Chandler GS, Brondfield S, Silverstein J, Wright F, de Dios K, Kim D, Mukherjee E, Krantz MS, Yao L, Johnson DB, Phillips EJ, Balko JM, Mohindra R, Quandt Z. irAE-GPT: Leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets. medRxiv : the preprint server for health sciences. 2025. PMID: 40093199
Rugo HS, Schmid P, Tolaney SM, Marmé F, Bardia A, Spears PA, Cortés J. A plain language summary of quality of life with sacituzumab govitecan treatment in the TROPiCS-02 study in participants with breast cancer (HR-positive/HER2-negative). Future oncology (London, England). 2025. PMID: 40045471
Rugo HS. Management of toxicities from antibody-drug conjugates. Clinical advances in hematology & oncology : H&O. 2025. PMID: 40153670
Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers EC. Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers. Volume 110 of Issue 3 Haematologica. 2025. PMID: 39540227
Fasching PA, Slamon D, Nowecki Z, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Chan A, Chia S, Martín M, Rugo HS, Loi S, Hurvitz S, Untch M, Afenjar K, Fresco R, Danyliv A, Ferrusi I, Li Z, Hortobagyi G. Health-related quality of life in patients with HR+/HER2- early breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor: results from the NATALEE trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 40019493
Facon T, Moreau P, Weisel K, Goldschmidt H, Usmani SZ, Chari A, Plesner T, Orlowski RZ, Bahlis N, Basu S, Hulin C, Quach H, O'Dwyer M, Perrot A, Jacquet C, Venner CP, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Cook G, Wang G, Pei H, Krevvata M, Carson R, Borgsten F, Kumar SK. Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025. PMID: 40016302